Programmed Death (PD)-1 Non-Small Cell Lung Cancer Global Market Report 2026

Description

Programmed death-1 (PD-1) non-small cell lung cancer (NSCLC) refers to a type of lung cancer in which tumors evade immune detection by exploiting the PD-1 pathway, an important immune checkpoint. PD-1 is a receptor on T cells that, when bound by its ligands PD-L1 or PD-L2, suppresses immune responses to prevent tissue damage. In NSCLC, tumors often overexpress PD-L1, allowing them to escape immune surveillance and progress.

The main types of PD-1 NSCLC therapies include monotherapy and combination therapy. Monotherapy involves treating the disease with a single drug, without combining it with other treatments. These therapies are applied across different lines of treatment, including first-line, second-line, and later stages, and are used by a variety of end users, such as hospitals, specialty cancer centers, academic and research institutions, and others.

Tariffs have affected the PD-1 NSCLC market by increasing the cost of imported immunotherapy drugs, biologics, and combination therapy agents, disrupting supply chains and raising treatment costs. Hospitals, specialty cancer centers, and academic institutes in regions like North America and Europe, which rely heavily on imported drugs, are most impacted. However, tariffs have also encouraged local production, research collaborations, and development of cost-optimized PD-1 therapies, potentially improving long-term access and affordability.

The programmed death (pd)-1 non-small cell lung cancer market research report is one of a series of new reports from The Business Research Company that provides programmed death (pd)-1 non-small cell lung cancer market statistics, including programmed death (pd)-1 non-small cell lung cancer industry global market size, regional shares, competitors with a programmed death (pd)-1 non-small cell lung cancer market share, detailed programmed death (pd)-1 non-small cell lung cancer market segments, market trends and opportunities, and any further data you may need to thrive in the programmed death (pd)-1 non-small cell lung cancer industry. This programmed death (pd)-1 non-small cell lung cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The programmed death (pd)-1 non-small cell lung cancer market size has grown strongly in recent years. It will grow from $27.5 billion in 2025 to $29.92 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to limited pd-1 inhibitors approved for nsclc, growing incidence of lung cancer, increasing physician awareness about immune checkpoint therapies, reliance on chemotherapy as standard care, early clinical trial successes of pembrolizumab and nivolumab.

The programmed death (pd)-1 non-small cell lung cancer market size is expected to see strong growth in the next few years. It will grow to $41.45 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to development of novel combination therapies, expansion of biomarker-driven personalized treatment, increasing adoption of mRNA vaccine-based therapies, growing investment in immuno-oncology research, rising government and private funding for cancer immunotherapy. Major trends in the forecast period include increased adoption of pd-1 monotherapy for nsclc, growth in combination therapies with chemotherapy, ctla-4 inhibitors, and vegf inhibitors, rising investment in targeted therapy and mrna vaccine research, expansion of first-line and second-line treatment options, integration of personalized medicine and biomarker testing in treatment planning.

The increasing adoption of personalized treatments is expected to drive the growth of the programmed death (PD)-1 non-small cell lung cancer market in the coming years. Personalized treatments are medical approaches tailored to an individual's genetic profile, lifestyle, and specific disease characteristics to achieve more effective and targeted outcomes. The rising demand for these treatments is fueled by greater access to genomic profiling and biomarker testing, which help identify specific mutations and biological markers, enabling clinicians to select therapies most likely to be effective. Personalized treatments support PD-1 non-small cell lung cancer (NSCLC) by customizing therapies based on a patient's genetic profile, tumor characteristics, and immune response. For instance, in February 2024, the Personalized Medicine Coalition reported that the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for rare diseases in 2023, compared to 6 in 2022. Therefore, the growing adoption of personalized treatments is propelling the PD-1 non-small cell lung cancer market.

Key companies in this market are focusing on clinical trials of innovative therapies, such as monotherapy, to improve patient outcomes. Monotherapy uses a single drug or therapy to treat a condition. For example, in March 2025, Akeso, Inc., a China-based biopharmaceutical company, announced positive results from its Phase III HARMONi-2 trial evaluating Ivonescimab (AK112) in combination with chemotherapy for first-line treatment of advanced NSCLC. The study met its primary endpoint by significantly extending progression-free survival compared to pembrolizumab, highlighting the potential of this dual-targeted bispecific antibody.

In February 2025, BioNTech SE, a Germany-based biotechnology company, acquired Biotheus Inc. for an undisclosed amount. This acquisition gave BioNTech access to Biotheus's lead asset, PM8002, a bispecific antibody targeting PD-L1 and vascular endothelial growth factor (VEGF)-A, currently in late-stage trials for NSCLC and other solid tumors. Biotheus Inc. is a China-based company specializing in multispecific biologics and immuno-oncology candidates, including PD-1 therapies for NSCLC.

Major companies operating in the programmed death (pd)-1 non-small cell lung cancer market are F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Incyte Corporation, Ono Pharmaceutical Co. Ltd., BeiGene Ltd., BioNTech SE, Shanghai Junshi Biosciences Co. Ltd., Akeso Inc., Arcus Biosciences Inc., Shandong Boan Biotechnology Co. Ltd., CStone Pharmaceuticals, iTeos Therapeutics Inc., Summit Therapeutics Inc., Shanghai Henlius Biotech Inc.

North America was the largest region in the programmed death (PD)-1 non-small cell lung cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the programmed death (pd)-1 non-small cell lung cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the programmed death (pd)-1 non-small cell lung cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The programmed death-1 (PD-1) non-small cell lung cancer market consists of revenues earned by entities by providing services such as clinical oncology services for immunotherapy administration, companion diagnostic testing, and comprehensive patient support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The programmed death-1 (PD-1) non-small cell lung cancer market also includes sales of pembrolizumab (Keytruda), nivolumab (Opdivo), and cemiplimab (Libtayo). Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses programmed death (pd)-1 non-small cell lung cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for programmed death (pd)-1 non-small cell lung cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The programmed death (pd)-1 non-small cell lung cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

Markets Covered:1) By Drug Type: Monotherapy; Combination Therapy
2) By Line of Therapy: First-line Treatment; Second-line And Beyond
3) By End User: Hospitals; Specialty Cancer Centers; Academic And Research Institutes; Other End Users
Subsegments:
1) By Monotherapy: Pembrolizumab (Keytruda); Nivolumab (Opdivo); Cemiplimab (Libtayo); Toripalimab; Tislelizumab; Camrelizumab; Dostarlimab; Other Monotherapy Drug Types
2) By Combination Therapy: Programmed Death (PD)-1 Inhibitor And Chemotherapy; Programmed Death (PD)-1 Inhibitor And Cytotoxic T-Lymphocyte Associated Protein (CTLA)-4 Inhibitor; Programmed Death (PD)-1 Inhibitor And Vascular Endothelial Growth Factor (VEGF) Inhibitor; Programmed Death (PD)-1 Inhibitor And Targeted Therapy; Programmed Death (PD)-1 Inhibitor And Radiation Therapy; Triple Combination Therapy; Programmed Death (PD)-1 Inhibitor And Messenger Ribonucleic Acid (mRNA) Vaccine; Other Combination Drug Types
Companies Mentioned: F. Hoffmann-La Roche Ltd; Merck & Co. Inc.; Sanofi S.A.; Novartis AG; GlaxoSmithKline plc; Regeneron Pharmaceuticals Inc.; Incyte Corporation; Ono Pharmaceutical Co. Ltd.; BeiGene Ltd.; BioNTech SE; Shanghai Junshi Biosciences Co. Ltd.; Akeso Inc.; Arcus Biosciences Inc.; Shandong Boan Biotechnology Co. Ltd.; CStone Pharmaceuticals; iTeos Therapeutics Inc.; Summit Therapeutics Inc.; Shanghai Henlius Biotech Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Product Code: PH6MPDP101_G26Q1

1. Executive Summary

1.1. Key Market Insights (2020-2035)
1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
1.3. Major Factors Driving the Market
1.4. Top Three Trends Shaping the Market

2. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Characteristics

2.1. Market Definition & Scope
2.2. Market Segmentations
2.3. Overview of Key Products and Services
2.4. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Attractiveness Scoring And Analysis
- 2.4.1. Overview of Market Attractiveness Framework
- 2.4.2. Quantitative Scoring Methodology
- 2.4.3. Factor-Wise Evaluation
Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation
2.4.5. Strategic Implications and Recommendations

3. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem
3.2. List Of Key Raw Materials, Resources & Suppliers
3.3. List Of Major Distributors and Channel Partners
3.4. List Of Major End Users

4. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Trends And Strategies

4.1. Key Technologies & Future Trends
- 4.1.1 Biotechnology, Genomics & Precision Medicine
- 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
- 4.1.3 Artificial Intelligence & Autonomous Intelligence
- 4.1.4 Industry 4.0 & Intelligent Manufacturing
- 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
4.2. Major Trends
- 4.2.1 Increased Adoption Of Pd-1 Monotherapy For Nsclc
- 4.2.2 Growth In Combination Therapies With Chemotherapy, Ctla-4 Inhibitors, And Vegf Inhibitors
- 4.2.3 Rising Investment In Targeted Therapy And Mrna Vaccine Research
- 4.2.4 Expansion Of First-Line And Second-Line Treatment Options
- 4.2.5 Integration Of Personalized Medicine And Biomarker Testing In Treatment Planning

5. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Analysis Of End Use Industries

5.1 Hospitals
5.2 Specialty Cancer Centers
5.3 Academic And Research Institutes
5.4 Oncology Clinics
5.5 Clinical Trial Centers

6. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Size, Comparisons And Growth Rate Analysis
7.3. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Segmentation

9.1. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Monotherapy, Combination Therapy
9.2. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
First-line Treatment, Second-line And Beyond
9.3. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Hospitals, Specialty Cancer Centers, Academic And Research Institutes, Other End Users
9.4. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Sub-Segmentation Of Monotherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Pembrolizumab (Keytruda), Nivolumab (Opdivo), Cemiplimab (Libtayo), Toripalimab, Tislelizumab, Camrelizumab, Dostarlimab, Other Monotherapy Drug Types
9.5. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Sub-Segmentation Of Combination Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Programmed Death (PD)-1 Inhibitor And Chemotherapy, Programmed Death (PD)-1 Inhibitor And CTLA-4 Inhibitor, Programmed Death (PD)-1 Inhibitor And VEGF Inhibitor, Programmed Death (PD)-1 Inhibitor And Targeted Therapy, Programmed Death (PD)-1 Inhibitor And Radiation Therapy, Triple Combination Therapy, Programmed Death (PD)-1 Inhibitor And mRNA Vaccine, Other Combination Drug Types

10. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Regional And Country Analysis

10.1. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

11.1. Asia-Pacific Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Line of Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

12.1. China Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Line of Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

13.1. India Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Line of Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

14.1. Japan Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Line of Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

15.1. Australia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Line of Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

16.1. Indonesia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Line of Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

17.1. South Korea Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Line of Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

18.1. Taiwan Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Line of Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

19.1. South East Asia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Line of Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

20.1. Western Europe Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Line of Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

21.1. UK Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Line of Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

22.1. Germany Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Line of Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

23.1. France Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Line of Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

24.1. Italy Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Line of Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

25.1. Spain Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Line of Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

26.1. Eastern Europe Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Line of Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

27.1. Russia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Line of Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

28.1. North America Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Line of Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

29.1. USA Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Line of Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

30.1. Canada Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Line of Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

31.1. South America Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Line of Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

32.1. Brazil Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Line of Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

33.1. Middle East Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Line of Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

34.1. Africa Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Segmentation By Line of Therapy, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Regulatory and Investment Landscape

36. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Competitive Landscape And Company Profiles

36.1. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Competitive Landscape And Market Share 2024
- 36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market - Company Scoring Matrix
- 36.2.1. Market Revenues
- 36.2.2. Product Innovation Score
- 36.2.3. Brand Recognition
36.3. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Company Profiles
- 36.3.1. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
- 36.3.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 36.3.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

37. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Other Major And Innovative Companies

Regeneron Pharmaceuticals Inc., Incyte Corporation, Ono Pharmaceutical Co. Ltd., BeiGene Ltd., BioNTech SE, Shanghai Junshi Biosciences Co. Ltd., Akeso Inc., Arcus Biosciences Inc., Shandong Boan Biotechnology Co. Ltd., CStone Pharmaceuticals, iTeos Therapeutics Inc., Summit Therapeutics Inc., Shanghai Henlius Biotech Inc.

38. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market

40. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market High Potential Countries, Segments and Strategies

40.1 Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market In 2030 - Countries Offering Most New Opportunities
40.2 Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market In 2030 - Segments Offering Most New Opportunities
40.3 Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market In 2030 - Growth Strategies
- 40.3.1 Market Trend Based Strategies
- 40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations
41.2. Currencies
41.3. Historic And Forecast Inflation Rates
41.4. Research Inquiries
41.5. The Business Research Company
41.6. Copyright And Disclaimer